Immunological treatment of liver tumors

被引:4
作者
Chiriva-Internati, Maurizio [1 ,2 ]
Grizzi, Fabio [3 ,4 ]
Jumper, Cynthia A. [2 ,5 ]
Cobos, Everardo [2 ,5 ]
Hermonat, Paul L. [6 ]
Frezza, Eldo E. [2 ,7 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Lubbock, TX 79430 USA
[2] SW Canc Treatment & Res Ctr, Lubbock, TX 79430 USA
[3] Ist Clin Humanitas, Sci Direct, I-20089 Rozzano, Italy
[4] Fdn M Rodriguez, Inst Quantitat Measures Med, I-20100 Milan, Italy
[5] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA
[6] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA
[7] Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA
关键词
Liver; Tumors; Surgery; Dendritic cell; Cytoreduction; Immunotherapy; Gene manipulation;
D O I
10.3748/wjg.v11.i42.6571
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although multiple options for the treatment of liver tumors have often been described in the past, including liver resection, radiofrequency ablation with or without hepatic pump insertion, laparoscopic liver resection and the use of chemotherapy, the potential of immunotherapy and gene manipulation is still largely unexplored. Immunological therapy by gene manipulation is based on the interaction between virus-based gene delivery systems and dendritic cells. Using viruses as vectors, it is possible to transduce dendritic cells with genes encoding tumor-associated antigens, thus inducing strong humoral and cellular immunity against the antigens themselves. Both chemotherapy and radiation therapy have the disadvantage of destroying healthy cells, thus causing severe side-effects. We need more precisely targeted therapies capable of killing cancer cells while sparing healthy cells. Our goal is to establish a new treatment for solid liver tumors based on the concept of cytoreduction, and propose an innovative algorithm. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:6571 / 6576
页数:6
相关论文
共 41 条
[1]  
Arthur JF, 1997, CANCER GENE THER, V4, P17
[2]  
ARYA SC, 1988, APMIS, V96, P30
[3]   Immunotherapeutic strategies for hepatocellular carcinoma [J].
Butterfield, LH .
GASTROENTEROLOGY, 2004, 127 (05) :S232-S241
[4]   Hepatocellular carcinoma: Current management and future trends [J].
Carr, BI .
GASTROENTEROLOGY, 2004, 127 (05) :S218-S224
[5]   Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24 [J].
Chiriva-Internati, M ;
Liu, Y ;
Weidanz, JA ;
Grizzi, F ;
You, H ;
Zhou, WP ;
Bumm, K ;
Barlogie, B ;
Mehta, JL ;
Hermonat, PL .
BLOOD, 2003, 102 (09) :3100-3107
[6]  
Chiriva-Internati M, 2002, EUR J IMMUNOL, V32, P30, DOI 10.1002/1521-4141(200201)32:1<30::AID-IMMU30>3.0.CO
[7]  
2-E
[8]   Tumor vaccine for ovarian carcinoma targeting sperm protein 17 [J].
Chiriva-Internati, M ;
Wang, ZQ ;
Salati, E ;
Timmins, P ;
Lim, SH .
CANCER, 2002, 94 (09) :2447-2453
[9]   Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. [J].
Chiriva-Internati, M ;
Wang, ZQ ;
Salati, E ;
Bumm, K ;
Barlogie, B ;
Lim, SH .
BLOOD, 2002, 100 (03) :961-965
[10]   Cancer immumotherapy: Avoiding the road to perdition [J].
Chiriva-Internati M. ;
Grizzi F. ;
Bright R.K. ;
Kast W.M. .
Journal of Translational Medicine, 2 (1)